| Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer CL Hodgkinson, CJ Morrow, Y Li, RL Metcalf, DG Rothwell, F Trapani, ... Nature medicine 20 (8), 897-903, 2014 | 786 | 2014 |
| Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer R Polañski, CL Hodgkinson, A Fusi, D Nonaka, L Priest, P Kelly, F Trapani, ... Clinical Cancer Research 20 (4), 926-937, 2014 | 344 | 2014 |
| Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists W Toy, H Weir, P Razavi, M Lawson, AU Goeppert, AM Mazzola, A Smith, ... Cancer discovery 7 (3), 277-287, 2017 | 336 | 2017 |
| Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer L Carter, DG Rothwell, B Mesquita, C Smowton, HS Leong, ... Nature medicine 23 (1), 114-119, 2017 | 314 | 2017 |
| Kinetochore localisation and phosphorylation of the mitotic checkpoint components Bub1 and BubR1 are differentially regulated by spindle events in human cells SS Taylor, D Hussein, Y Wang, S Elderkin, CJ Morrow Journal of cell science 114 (24), 4385-4395, 2001 | 260 | 2001 |
| Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20 CJ Morrow, A Tighe, VL Johnson, MIF Scott, C Ditchfield, SS Taylor Journal of cell science 118 (16), 3639-3652, 2005 | 221 | 2005 |
| The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer A Lallo, KK Frese, CJ Morrow, R Sloane, S Gulati, MW Schenk, F Trapani, ... Clinical Cancer Research 24 (20), 5153-5164, 2018 | 146 | 2018 |
| Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study CJ Morrow, F Trapani, RL Metcalf, G Bertolini, CL Hodgkinson, ... Annals of Oncology 27 (6), 1155-1160, 2016 | 111 | 2016 |
| Identification and targeting of long-term tumor-propagating cells in small cell lung cancer NS Jahchan, JS Lim, B Bola, K Morris, G Seitz, KQ Tran, L Xu, F Trapani, ... Cell reports 16 (3), 644-656, 2016 | 88 | 2016 |
| Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist JS Scott, TA Moss, A Balazs, B Barlaam, J Breed, RJ Carbajo, ... Journal of Medicinal Chemistry 63 (23), 14530-14559, 2020 | 66 | 2020 |
| Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1 LRE Harrison, D Micha, M Brandenburg, KL Simpson, CJ Morrow, ... The Journal of Clinical Investigation 121 (3), 1075-1087, 2011 | 65 | 2011 |
| The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells T Klymenko, M Brandenburg, C Morrow, C Dive, G Makin Molecular cancer therapeutics 10 (12), 2373-2383, 2011 | 38 | 2011 |
| Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA CJ Morrow, A Gray, C Dive FEBS letters 579 (23), 5123-5128, 2005 | 38 | 2005 |
| Inhibition of PI3K/BMX cell survival pathway sensitizes to BH3 mimetics in SCLC DS Potter, M Galvin, S Brown, A Lallo, CL Hodgkinson, F Blackhall, ... Molecular cancer therapeutics 15 (6), 1248-1260, 2016 | 37 | 2016 |
| Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with … R Baird, M Oliveira, EMC Gil, MR Patel, B Bermejo de las Heras, ... Cancer research 81 (4_Supplement), PS11-05-PS11-05, 2021 | 32 | 2021 |
| BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737 DS Potter, P Kelly, O Denneny, V Juvin, LR Stephens, C Dive, CJ Morrow Neoplasia 16 (2), 147-W16, 2014 | 32 | 2014 |
| Tricyclic indazoles—a novel class of selective estrogen receptor degrader antagonists JS Scott, A Bailey, D Buttar, RJ Carbajo, J Curwen, PRJ Davey, ... Journal of Medicinal Chemistry 62 (3), 1593-1608, 2019 | 30 | 2019 |
| Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters CJ Morrow, M Ghattas, C Smith, H Bönisch, RA Bryce, DM Hickinson, ... Cancer research 70 (14), 5931-5941, 2010 | 28 | 2010 |
| Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs C Martin-Fernandez, J Bales, C Hodgkinson, A Welman, MJ Welham, ... Molecular Cancer Research 7 (6), 955-965, 2009 | 28 | 2009 |
| Somatically mutated ABL 1 is an actionable and essential NSCLC survival gene E Testoni, NL Stephenson, P Torres‐Ayuso, AA Marusiak, EW Trotter, ... EMBO molecular medicine 8 (2), 105-116, 2016 | 25 | 2016 |
